Drug intelligence / Profile preview

anti-CD19 CAR-T

Development stage: Unknown
Lead developer: The First Affiliated Hospital of Wenzhou Medical University
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

anti-CD19 CAR-T is an autologous chimeric antigen receptor (CAR) T-cell therapy developed by the First Affiliated Hospital of Wenzhou Medical University. The therapy involves the ex vivo modification of a patient's own T cells to express a CAR targeting the CD19 antigen, which is highly expressed on B-cell lineage cells. This treatment is specifically being investigated in Phase I clinical trials as a consolidative therapy followed by allogeneic stem cell transplantation for patients with refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL), chronic lymphocytic leukemia (CLL), and various B-cell lymphomas.

Other names: anti-CD19 CAR-T cellsanti-CD-19 CAR-T cellsanti-CD 19 CAR-T cellsCD19 CAR-TCD-19 CAR-TCD 19 CAR-T

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on anti-CD19 CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on anti-CD19 CAR-T.

Explore the full profile